Physician profile
Sudeshna Mitra
NPI 1831153469
$3,178.01
in general payments reported to CMS, 2019-2025
29 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,463 · 2020: $431 · 2021: $375 · 2022: $177 · 2023: $390 · 2024: $219 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $437.80 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $397.43 | 2019-2024 | Farxiga, Breztri |
| Novo Nordisk INC | $292.83 | 2019-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $221.84 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.41 | 2019-2025 | Synjardy, Jardiance |
| Pfizer INC. | $177.92 | 2019-2021 | |
| Lilly USA, LLC | $154.29 | 2019-2021 | |
| Glaxosmithkline, LLC. | $147.86 | 2019-2024 | Shingrix, Arexvy |
| Boston Scientific Corporation | $125.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $123.37 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $99.37 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.05 | 2019-2023 | Xifaxan |
| Abbvie INC. | $89.51 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $89.10 | 2019-2024 | Capvaxive |
| Amgen INC. | $87.73 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $67.19 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $62.36 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $47.46 | 2019-2020 | |
| Allergan, INC. | $38.76 | 2019 | |
| Esperion Therapeutics, INC. | $37.71 | 2021 | |
| Astellas Pharma US INC | $23.58 | 2019-2020 | |
| Abbott Laboratories | $22.06 | 2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $21.12 | 2022 | |
| Nevro Corp. | $21.10 | 2019 | |
| Medtronic Vascular, INC. | $20.09 | 2019 | |
| Shield Therapeutics INC | $19.69 | 2023 | Accrufer |
| Janssen Pharmaceuticals, INC | $15.56 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.10 | 2019 | |
| Ibsa Pharma INC. | $12.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudeshna Mitra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.